ATE292685T1 - Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe - Google Patents

Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe

Info

Publication number
ATE292685T1
ATE292685T1 AT98942007T AT98942007T ATE292685T1 AT E292685 T1 ATE292685 T1 AT E292685T1 AT 98942007 T AT98942007 T AT 98942007T AT 98942007 T AT98942007 T AT 98942007T AT E292685 T1 ATE292685 T1 AT E292685T1
Authority
AT
Austria
Prior art keywords
influenza
virus
variants
vaccines
constructions
Prior art date
Application number
AT98942007T
Other languages
English (en)
Inventor
A Michael Frace
Alexander I Klimov
Jacqueline M Katz
Original Assignee
Ct Disease Contr & Prevention
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Disease Contr & Prevention filed Critical Ct Disease Contr & Prevention
Application granted granted Critical
Publication of ATE292685T1 publication Critical patent/ATE292685T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AT98942007T 1997-08-06 1998-08-06 Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe ATE292685T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/906,930 US6169175B1 (en) 1997-08-06 1997-08-06 Preparation and use of recombinant influenza A virus M2 construct vaccines
PCT/US1998/016379 WO1999028478A1 (en) 1997-08-06 1998-08-06 Preparation and use of recombinant influenza a virus m2 constructs and vaccines

Publications (1)

Publication Number Publication Date
ATE292685T1 true ATE292685T1 (de) 2005-04-15

Family

ID=25423243

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98942007T ATE292685T1 (de) 1997-08-06 1998-08-06 Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe

Country Status (10)

Country Link
US (1) US6169175B1 (de)
EP (1) EP1002093B1 (de)
JP (1) JP2002508153A (de)
AT (1) ATE292685T1 (de)
AU (1) AU755475B2 (de)
CA (1) CA2299677C (de)
DE (1) DE69829668T2 (de)
ES (1) ES2239401T3 (de)
NZ (1) NZ502398A (de)
WO (1) WO1999028478A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007839A2 (en) * 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
US7731972B1 (en) * 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
EP1222281B1 (de) * 1999-09-30 2006-11-15 University of Washington Immunologisch relevante antigene aus herpes simplexvirus
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
DK1450856T3 (da) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US20030219442A1 (en) * 2002-03-13 2003-11-27 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
EP2351770A1 (de) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molekulare Antigen-Anordnung durch Verwendung eines Virus ähnlichen Partikels vom Virus ap205
EP1523334A2 (de) 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-träger-konjugate und ihre verwendung
CA2492930C (en) 2002-07-19 2013-01-08 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
AU2004220549B2 (en) * 2003-03-07 2007-07-05 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Influenza virus vaccine
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ZA200507562B (en) 2003-03-26 2006-11-29 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2006061723A2 (en) 2004-12-06 2006-06-15 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
TW200745158A (en) * 2006-03-07 2007-12-16 Vaxinnate Corp Compositions that include hemagglutinin, methods of making and methods of use thereof
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
US8148085B2 (en) * 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
EP2043681B1 (de) 2006-07-14 2015-10-07 Sanofi Pasteur Biologics, LLC Konstruktion rekombinanter virenimpfstoffe durch direkten transposon-vermittelten einsatz fremder immunologischer determinanten in vektorvirusproteine
MX2009003300A (es) 2006-09-29 2009-08-12 Sanofi Pasteur Biologics Co Vectores de rhinovirus recombinantes.
US9474798B2 (en) * 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP3115060A1 (de) 2008-04-18 2017-01-11 VaxInnate Corporation Flagellin deletionsmutanten und deren verwendung
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US9044447B2 (en) 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
WO2011024748A1 (ja) 2009-08-28 2011-03-03 一般財団法人化学及血清療法研究所 インフルエンザm2由来の改変ペプチドワクチン
EP2493912B1 (de) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation Rekombinante influenzaviren mit hohem titer und erhöhter replikation in vero-zellen
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus

Also Published As

Publication number Publication date
US6169175B1 (en) 2001-01-02
AU9015098A (en) 1999-06-16
NZ502398A (en) 2002-04-26
JP2002508153A (ja) 2002-03-19
EP1002093A1 (de) 2000-05-24
ES2239401T3 (es) 2005-09-16
AU755475B2 (en) 2002-12-12
DE69829668T2 (de) 2006-03-09
EP1002093B1 (de) 2005-04-06
CA2299677A1 (en) 1999-06-10
DE69829668D1 (de) 2005-05-12
WO1999028478A1 (en) 1999-06-10
CA2299677C (en) 2011-07-26

Similar Documents

Publication Publication Date Title
ATE292685T1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
CY1106806T1 (el) Dna και πολυπεπτιδια ανθρωπινης tslp
ATE328068T1 (de) Papillomavirus vakzine
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
DK0835315T3 (da) Vaccine til porcint reproduktivt og respiratorisk syndrom virus
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
ATE482272T1 (de) Zytokinproteinfamilie
BR9812240A (pt) Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica
FI20070041A (fi) Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
ATE312923T1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
ATE174963T1 (de) Klonierung und expression eines rhoptry- assoziierten proteins aus p. falciparum
ZA896942B (en) Allelic variants of plasmodium falciparum merozoite surface antigen
NZ512308A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
EP0953642A4 (de) Antigenprotein aus infektiöse laryngotracheitis viren
GB2341606A (en) Glycosylation peptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1002093

Country of ref document: EP

REN Ceased due to non-payment of the annual fee